We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
Read MoreHide Full Article
Key Takeaways
CODX received its first issued patent for the Co-Dx PCR platform from the Australian Patent Office.
CODX's patent covers the PCR Pro instrument and proprietary test cups for point-of-care use.
CODX is expanding global IP protection as the PCR platform remains under regulatory review.
CoDiagnostics (CODX - Free Report) recently announced that the Australian Patent Office has granted a patent covering its new Co-Dx PCR platform, marking the first patent issued for this point-of-care technology.
From an investor perspective, the patent strengthens CODX’s long-term commercialization strategy by securing IP in a region that could become an important future market. While the platform is still under regulatory review and not yet available for sale, the milestone supports management’s push to expand global protection for its PCR technology as it targets decentralized and point-of-care testing opportunities.
Likely Trend of CODX Stock Following the News
Following the announcement, CODX shares lost 21.1% at yesterday’s market closing. Shares of the company have lost 35.5% in the last six-month period against the industry’s 6.2% growth. The S&P 500 has gained 14.1% in the same time frame.
In the long run, the Australian patent strengthens CODX by securing defensible intellectual property around its point-of-care PCR platform, reducing competitive risk and protecting future commercialization potential. The added IP coverage enhances CODX’s leverage with potential partners and distributors while preserving pricing power and recurring revenue opportunities tied to instruments and consumables, supporting a more durable platform-driven growth story once regulatory approvals are in place.
CODX currently has a market capitalization of $13.9 million.
Image Source: Zacks Investment Research
More on the News
CODX announced that the Australian Patent Office has granted Patent No. AU2022270084A1, marking the first issued patent for its new Co-Dx PCR platform. Filed in May 2022 and granted in June 2025, the patent provides broad protection covering the system and methods used for nucleic acid detection and analysis. The claims specifically include the design and operation of the Co-Dx PCR Pro instrument and its proprietary test cups, supporting high-quality PCR testing in point-of-care and decentralized settings rather than traditional labs.
From a strategic standpoint, securing patent protection in Australia strengthens the company’s global IP portfolio as it evaluates future commercialization and partnership opportunities in the region. The move is timely given Australia’s recent record flu season, which highlights growing demand for rapid and accessible molecular diagnostics.
The patent also supports the long-term commercial potential of the Co-Dx PCR Flu A/B, COVID, and RSV multiplex test, currently in clinical performance testing. While the platform remains under regulatory review and is not yet available for sale, the patent positions CODX to protect its technology and future revenue opportunities ahead of broader market entry.
Favorable Industry Prospects for CODX
Per a report by Grand View Research, the global molecular diagnostics market size was estimated at $18.85 billion in 2025 and is projected to reach $25.59 billion by 2033, expanding at a CAGR of 4.06% from 2026 to 2033.
Key drivers of this growth include ongoing technological advancements, a steadily aging population, and rising demand for precise, efficient genetic testing solutions.
Other Recent Developments for CODX
Recently, CODX announced that an in-silico analysis of the Co-Primers used in its Logix Smart ABC test demonstrated high homology across roughly 3,900 influenza sequences, supporting strong and consistent detection of influenza A, influenza B and COVID-19. Notably, the results confirmed comparable reactivity against the influenza A H3N2 subclade K, reinforcing confidence in the test’s robustness as flu strains evolve and highlighting the durability of CODX’s primer design in maintaining diagnostic accuracy over time.
CODX’s Zacks Rank & Other Key Picks
Currently, CODX carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted earnings per share (EPS) of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2, reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
Key Takeaways
CoDiagnostics (CODX - Free Report) recently announced that the Australian Patent Office has granted a patent covering its new Co-Dx PCR platform, marking the first patent issued for this point-of-care technology.
From an investor perspective, the patent strengthens CODX’s long-term commercialization strategy by securing IP in a region that could become an important future market. While the platform is still under regulatory review and not yet available for sale, the milestone supports management’s push to expand global protection for its PCR technology as it targets decentralized and point-of-care testing opportunities.
Likely Trend of CODX Stock Following the News
Following the announcement, CODX shares lost 21.1% at yesterday’s market closing. Shares of the company have lost 35.5% in the last six-month period against the industry’s 6.2% growth. The S&P 500 has gained 14.1% in the same time frame.
In the long run, the Australian patent strengthens CODX by securing defensible intellectual property around its point-of-care PCR platform, reducing competitive risk and protecting future commercialization potential. The added IP coverage enhances CODX’s leverage with potential partners and distributors while preserving pricing power and recurring revenue opportunities tied to instruments and consumables, supporting a more durable platform-driven growth story once regulatory approvals are in place.
CODX currently has a market capitalization of $13.9 million.
Image Source: Zacks Investment Research
More on the News
CODX announced that the Australian Patent Office has granted Patent No. AU2022270084A1, marking the first issued patent for its new Co-Dx PCR platform. Filed in May 2022 and granted in June 2025, the patent provides broad protection covering the system and methods used for nucleic acid detection and analysis. The claims specifically include the design and operation of the Co-Dx PCR Pro instrument and its proprietary test cups, supporting high-quality PCR testing in point-of-care and decentralized settings rather than traditional labs.
From a strategic standpoint, securing patent protection in Australia strengthens the company’s global IP portfolio as it evaluates future commercialization and partnership opportunities in the region. The move is timely given Australia’s recent record flu season, which highlights growing demand for rapid and accessible molecular diagnostics.
The patent also supports the long-term commercial potential of the Co-Dx PCR Flu A/B, COVID, and RSV multiplex test, currently in clinical performance testing. While the platform remains under regulatory review and is not yet available for sale, the patent positions CODX to protect its technology and future revenue opportunities ahead of broader market entry.
Favorable Industry Prospects for CODX
Per a report by Grand View Research, the global molecular diagnostics market size was estimated at $18.85 billion in 2025 and is projected to reach $25.59 billion by 2033, expanding at a CAGR of 4.06% from 2026 to 2033.
Key drivers of this growth include ongoing technological advancements, a steadily aging population, and rising demand for precise, efficient genetic testing solutions.
Other Recent Developments for CODX
Recently, CODX announced that an in-silico analysis of the Co-Primers used in its Logix Smart ABC test demonstrated high homology across roughly 3,900 influenza sequences, supporting strong and consistent detection of influenza A, influenza B and COVID-19. Notably, the results confirmed comparable reactivity against the influenza A H3N2 subclade K, reinforcing confidence in the test’s robustness as flu strains evolve and highlighting the durability of CODX’s primer design in maintaining diagnostic accuracy over time.
CODX’s Zacks Rank & Other Key Picks
Currently, CODX carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted earnings per share (EPS) of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2, reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.